Noven regains methylphenidate patch rights from Shire
This article was originally published in Scrip
Executive Summary
Noven Pharmaceuticals has regained the global rights to Daytrana (methylphenidate transdermal system) from Shire. The patch treatment for attention-deficit hyperactivity disorder in patients aged 6 to 17 years was developed by Noven and licensed to Shire in 2003.